Dmitry Klokol
Stellar Biomolecular Research, Frankfurt am Main, Germany
Title: HRT-free management of premature andropause with advanced organ-specific peptide therapy
Biography
Biography: Dmitry Klokol
Abstract
Management of early andropause is one of the important issues in andrology. Early or premature andropause is associated with such symptoms as loss of libido and morning penile erection, erectile dysfunction, demonstration of low testosterone levels, and ultimately male infertility. Needless to mention that reduction of sexual hormonal expression plays a pivotal role in aging process. Genetics, previous illnesses, certain medical procedures, and environmental factors are the leading etiologic factors of premature andropause development.
Premature andropause is often responsible for cognitive decline, dyslipidemia, diabetes, obesity, fatigue, and loss of muscle bulk. Biochemical signs of premature andropause are reduction of basal and free testosterone levels at 15% or more below normal range.
Conventionally this condition is treated with testosterone replacement therapy. However, testosterone replacement may carry risk of cardiac hypertrophy, prostate hyperplasia and aggravate symptoms in men with prostate cancer.
The objective of this study was to assess efficacy of biohormonal therapy using a combination of organ-specific peptides-extracts (Mito Organelles™, SBI, MF+, Germany) from hypothalamus, pituitary gland, adrenals, testicles and liver as a safer alternative to the testosterone replacement. The duration of the treatment is 4 months and does not require continuous prolonged drug intake. Organ-specific peptide therapy has high efficacy rate with no adverse reactions observed. Most of the patients had dramatic improvement of symptoms and increase of testosterone levels. None of the observed patients had need in further testosterone replacement.
Obtained preliminary results are promising and such therapeutic approach needs further studies and evaluation of late results and outcomes.